Parenteral Antiplatelet Agents in PCI

[1]  B. Hansen,et al.  Comparative Effectiveness and Safety of a Catheterization Laboratory–Only Eptifibatide Dosing Strategy in Patients Undergoing Percutaneous Coronary Intervention , 2015, Circulation. Cardiovascular interventions.

[2]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[3]  H. Thiele,et al.  Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[4]  Deepak L. Bhatt,et al.  Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data , 2013, The Lancet.

[5]  Gregg W Stone,et al.  Effect of platelet inhibition with cangrelor during PCI on ischemic events. , 2013, The New England journal of medicine.

[6]  Harlan M Krumholz,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[7]  G. Stone,et al.  Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. , 2012, JAMA.

[8]  M. Valgimigli,et al.  Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. , 2012, American heart journal.

[9]  G. Schuler,et al.  Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial , 2012, The Lancet.

[10]  M. Price,et al.  Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. , 2012, JAMA.

[11]  Jörg Hausleiter,et al.  Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. , 2011, The New England journal of medicine.

[12]  P. Stella,et al.  Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. , 2010, Journal of the American College of Cardiology.

[13]  Gregg W Stone,et al.  Platelet inhibition with cangrelor in patients undergoing PCI. , 2009, The New England journal of medicine.

[14]  Deepak L. Bhatt,et al.  Intravenous platelet blockade with cangrelor during PCI. , 2009, The New England journal of medicine.

[15]  R. Califf,et al.  Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.

[16]  G. De Luca,et al.  Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials , 2009, European heart journal.

[17]  E. Topol,et al.  Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. , 2009, JACC. Cardiovascular interventions.

[18]  E. Antman,et al.  The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis , 2009, Journal of the American College of Cardiology.

[19]  S. Nekolla,et al.  Abciximab in Patients With Acute ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Clopidogrel Loading: A Randomized Double-Blind Trial , 2009, Circulation.

[20]  J. Saw,et al.  Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. , 2009, Journal of the American College of Cardiology.

[21]  G. Montalescot.  Mechanical reperfusion: treat well, treat on time too , 2008, The Lancet.

[22]  J. Ottervanger,et al.  Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial , 2008, The Lancet.

[23]  E. Topol,et al.  Facilitated PCI in patients with ST-elevation myocardial infarction. , 2008, The New England journal of medicine.

[24]  J. Ware,et al.  Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. , 2007, JAMA.

[25]  Adelaide,et al.  Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.

[26]  A. Kastrati,et al.  Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. , 2006, JAMA.

[27]  R. Ferrari,et al.  The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. , 2004, Journal of the American College of Cardiology.

[28]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.

[29]  A. Kastrati,et al.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[30]  J. J. Griffin,et al.  Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. , 2002, The New England journal of medicine.

[31]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials , 2002, The Lancet.

[32]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.